Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population

This study evaluated uptake of the first biosimilar biologic, filgrastim-sndz (Zarxio), relative to its originator filgrastim product (Neupogen). These products share multiple indications for neutropenia and malignancy. Tbo-filgrastim (Granix), a stand-alone alternative biologic with a single indica...

Full description

Saved in:
Bibliographic Details
Published inJAMA : the journal of the American Medical Association Vol. 320; no. 9; pp. 929 - 931
Main Authors Kozlowski, Steven, Birger, Noy, Brereton, Stephaeno, McKean, Stephen J, Wernecke, Michael, Christl, Leah, Kelman, Jeffrey A
Format Journal Article
LanguageEnglish
Published United States American Medical Association 04.09.2018
Subjects
Aged
Aged, 80 and over
Biological products
Biosimilar Pharmaceuticals - therapeutic use
Drug Utilization - statistics & numerical data
Female
Filgrastim - therapeutic use
Government programs
Health care
Health care expenditures
Hematologic Agents - therapeutic use
Humans
Letter
Letters
Male
Malignancy
Medicare
Medicare Part B
Neutropenia
Population studies
Research Letter
United States
Online AccessGet full text

Cover

More Information
Summary:This study evaluated uptake of the first biosimilar biologic, filgrastim-sndz (Zarxio), relative to its originator filgrastim product (Neupogen). These products share multiple indications for neutropenia and malignancy. Tbo-filgrastim (Granix), a stand-alone alternative biologic with a single indication, was also evaluated.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2018.9014